Skip to content

    Natco Pharma

    NATCOPHARM
    Healthcare·12 Feb 2026
    Management Summary

    Natco Pharma delivered a strong Q3 FY26, reporting consolidated revenue of ₹705.4 crores and a robust EBITDA margin of 30.7%, with net profit at ₹151.3 crores. The company declared an interim dividend and is focused on geographical expansion and strategic acquisitions, leveraging its significant cash reserves. Key pipeline products like semaglutide and NCE investments such as eGenesis are central to future growth, though regulatory and competitive challenges persist.

    Highlights

    5
    • Consolidated total revenue for Q3 FY26 grew to ₹705.4 crores from ₹651.1 crores in Q3 FY25, an 8.34% YoY increase.

    • Achieved a healthy EBITDA of ₹216.8 crores with a margin of 30.7% for Q3 FY26.

    • Reported a net profit of ₹151.3 crores for the quarter on a consolidated basis.

    • Declared an interim dividend of ₹1.5 per equity share during Q3 FY26.

    • Strong performance from subsidiaries in Brazil and Canada, and the Middle East, contributing to export formulations growth with zero Revlimid contribution this quarter.

    Concerns

    3
    • Ongoing litigation for erdafitinib and olaparib, making launch timelines premature and uncertain.

    • Semaglutide market in India is expected to be extremely competitive with many generics.

    • Management is not considering a share buyback despite a net cash position of ₹2,500 crores, prioritizing cash for large acquisitions.

    Key financials

    Metrics

    9

    Periods

    2

    Headline

    7
    • Consolidated Revenue
      ₹705.4 Cr
      YoY+8.3%
    • EBITDA
      ₹216.8 Cr
    • EBITDA Margin
      30.7%
    • Consolidated Net Profit
      ₹151.3 Cr
    • NATCO Adcock Profit Reflection (Nov-Dec 2025)
      ₹29.65 Cr

    H1 FY26

    2
    • Adcock Ingram Revenue
      ₹2,464 Cr
    • Adcock Ingram PAT
      ₹198 Cr

    Capital allocation

    5
    high confidence
    CategoryHeadline
    Debt

    Net ₹2,500 crores

    Dividend

    ₹1.5/share (interim)

    M&A

    Adcock Ingram Holdings

    acquisition · integrated

    M&A

    Undisclosed Acquisition Targets

    acquisition · announced

    Liquidity

    Cash ₹2,500 crores

    Company has sufficient cash to pursue large acquisitions and is preserving it for this purpose.

    Guidance & targets

    11
    CategoryTargetPriority
    Revenue
    Consolidated Revenue
    ₹4,300 crores
    High
    Profitability
    Consolidated PAT
    ₹1,280-1,300 crores
    High
    Profitability
    Adcock Ingram PAT Contribution
    ₹35-40 crores per quarter
    Medium
    Amortization
    Adcock Ingram Amortization
    ₹10-14 crores per year / ₹3 crores per quarter
    Medium
    Domestic Business Growth
    India Business Growth
    >20%
    High
    De-merger
    Crop Health Sciences De-merger
    October/November
    Medium
    Product Launches
    US ANDA Approvals (non-Para IV)
    Expected in April-June quarter
    High
    Product Launches
    US Shared FTF Launch
    One expected next financial year
    High
    Product Filings
    Complex Generic Filings
    8 products
    Medium
    Regulatory
    Chennai Plant FDA Classification
    Expected in next 30-40 days
    High
    Regulatory
    Vizag Plant FDA Inspection
    Expected this year
    Medium

    Semaglutide Market Uptake and Competition

    Next quarter
    CurrentMarket expected to be competitive, uptake clarity expected next quarterly call.
    TargetInitial market traction and competitive landscape for semaglutide in India.

    Why it matters

    Semaglutide is a key driver for the domestic business, targeted to grow >20% this year.

    If you ask me, I think the next quarterly call, I'll give you an idea of how the uptake is and what I believe the market will entail in capacity because at this time, it's very early, because there are a lot of permutations combinations like you know that Mounjaro is doing better than semaglutide in the Indian market. But obviously, with a lower price, there will be some uptake.

    How to verify

    detailed_narrative

    Risks & concerns

    4
    RiskSeverity

    Semaglutide Market Competition

    The semaglutide market in India is expected to be extremely competitive with many generics, potentially impacting uptake and pricing.Management acknowledged

    medium

    Litigation Delays for Pipeline Products

    Ongoing litigation for products like erdafitinib and olaparib is delaying launch timelines, creating uncertainty for future revenue streams.Management acknowledged

    medium

    High-Risk NCE Investments

    Investments in novel technologies like eGenesis (CRISPR-Cas9 for organ transplantation) are high-risk, with success dependent on clinical trial outcomes over several years.Management acknowledged

    medium

    Adcock Ingram Shareholding Limitation

    Bidvest is currently not interested in selling more shares of Adcock Ingram, which limits Natco's ability to quickly increase its stake and achieve higher turnover targets through this route.Management acknowledged

    low

    Q&A highlights

    8

    “GLP-1 approval is expected sometime this month. It's pending at DCGI. Capacity right now, we are outsourcing from OneSource. As of now, we don't have any capacity. So right now, our tie-up is for India OneSource we're doing and then we're not actively pursuing emerging markets. We're actively pursuing only regulated markets.”

    Clarifies the company's immediate strategy for semaglutide launch in India, including outsourcing and market focus, highlighting the competitive landscape.

    asked by Gautam

    3 min read7 chapters

    Detailed Narrative

    01

    Q3 FY26 Financial Performance Overview

    Natco Pharma reported a consolidated total revenue of ₹705.4 crores for Q3 FY26, marking an 8.34% increase from ₹651.1 crores in Q3 FY25. The company achieved an EBITDA of ₹216.8 crores, translating to a healthy margin of 30.7%. Consolidated net profit for the quarter stood at ₹151.3 crores, reflecting a solid financial performance.

    02

    Adcock Ingram Contribution and Amortization Impact

    The company's share of profit from its associated company, Adcock Ingram Holdings, for the period of November 10 to December 31, 2025, was ₹29.65 crores. After accounting for a one-time📎 amortization of ₹18.75 crores, the net profit reflection in Natco's financials was ₹10.9 crores. Management anticipates a recurring quarterly PAT addition of ₹35-40 crores from Adcock, with an annual amortization of ₹10-14 crores, or approximately ₹3 crores per quarter.

    03

    Semaglutide Launch Strategy and Market Outlook

    Natco Pharma is preparing for the launch of semaglutide (Ozempic and Wegovy) in India, with Ozempic having received SEZ committee clearance and a license expected shortly. The fill-finish capacity for the Indian market is currently outsourced. Management expects the market to be highly competitive with many generics but aims for its domestic business, currently annualized at ₹450-460 crores, to grow by over 20% this year, primarily driven by semaglutide.

    04

    NCE Pipeline and eGenesis Investment

    The company is actively pursuing five New Chemical Entity (NCE) ideas, with eGenesis (xenotransplantation using CRISPR-Cas9 technology) highlighted as the most exciting. Natco has invested $8 million in eGenesis, which aims to genetically modify pig organs for human transplantation. Management views this as a high-risk, disruptive technology with the potential for a 'home run' in 2-3 years if trials involving 25-30 patients demonstrate success, noting one patient has done well for 6 months and another is progressing positively.

    05

    Capital Allocation for Acquisitions and Geographical Expansion

    With a net cash position of approximately ₹2,500 crores, Natco Pharma is prioritizing cash for large acquisitions rather than a share buyback. The company is actively pursuing 2-3 acquisition targets, aiming to close 1-2 in 2026, focusing on emerging markets and established brand businesses. Management believes opportunities outside India offer better returns and is building geographical footprints in Canada, US, Brazil, and South Africa, with Western Europe identified as a key market not yet fully present in.

    06

    R&D Strategy and Operational Efficiency

    The R&D budget allocation was strategically managed in the September quarter, anticipating the decline in Revlimid contribution, with most R&D for the next few months already covered. While R&D spend typically hovers around 8% of sales, the company is recalibrating its approach, including exploring partnerships for complex generics to share expenditure and reduce risk, ensuring continued investment in its pipeline while maintaining momentum.

    07

    Manufacturing Plant Regulatory Updates

    Natco Pharma provided updates on its four FDA-approved plants. The warning letter for the Kothur facility has been removed, and the Mekaguda plant received clearance after inspection this year. The Chennai plant was inspected this year and is awaiting classification, with observations deemed procedural, and classification expected within 30-40 days. The Vizag formulation facility is also due for an inspection this year, with the last inspection having occurred 2.5-3 years ago.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.